Loading
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
Regular session
$20.055
+$0.925 · +4.84%
Regular session · ET · Market data may be delayed.
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
Day range
Current $20.055
52-week range
Current $20.055
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
45
Fair Value
Sentiment
48
Mixed
Risk
72
High Risk
Momentum
75
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
Day range
Current $20.055
52-week range
Current $20.055
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | — | 3.49M USD | 8.96M USD | — |
| Gross profit | — | — | −3.49M USD | −8.96M USD | — |
| Research and development | 321.53M USD | 93.31M USD | 94.32M USD | 64.55M USD | 47.53M USD |
| Selling, general, and administrative | 50.11M USD | 27.88M USD | 31.72M USD | 19.91M USD | 21.49M USD |
| Operating expenses | 371.64M USD | 121.19M USD | 122.54M USD | 84.46M USD | 69.02M USD |
| Interest income | 5.87M USD | 4.27M USD | 8.17M USD | 1.32M USD | 119K USD |
| Depreciation and amortization | 2.89M USD | 3.53M USD | 3.49M USD | 2.53M USD | 1.43M USD |
| Operating income | −371.64M USD | −121.19M USD | −126.04M USD | −93.42M USD | −69.02M USD |
| Net income | −695.98M USD | −116.91M USD | −117.86M USD | −92.09M USD | −68.9M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$29.00
44.60% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Sep 19, 2025 | 1:20 | — | — |
Effective Sep 19, 2025
1:20
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI34.86M0.00%2.3T USD0.03%$381.73+0.57%
State Street SPDR S&P Biotech ETFXBI21.67M0.21%10.11B USD0.35%$154.43+3.44%
iShares Russell 2000 ETFIWM19.38M0.02%77.7B USD0.19%$278.93+0.49%
Vanguard Extended Market ETFVXF11.18M0.01%95.4B USD0.05%$234.8+0.71%
Vanguard Russell 2000 ETFVTWO5.27M0.03%18B USD0.06%$112.67+0.50%
Fidelity Enhanced Small Cap ETFFESM4.73M0.07%6.41B USD0.28%$45.485+0.52%
iShares Russell 2000 Growth ETFIWO4.7M0.03%14.04B USD0.24%$356.7+0.91%
Schwab U.S. Small-Cap ETFSCHA3.88M0.02%21.73B USD0.03%$32.795+0.41%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
